MAPT and Alzheimer disease: In contrast, and based on the strong relationships with the amyloid-beta tracer, we suggest that 11C-PBB3 could, in the early symptomatic stages of AD, show preferential binding to tau deposits spatially related to amyloid-beta, which could explain its limited association with more downstream markers of the disease (i.e. neurodegeneration and cognitive impairment).